This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple
by Zacks Equity Research
Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple
Is AbbVie (ABBV) Stock a Solid Choice Right Now?
by Zacks Equity Research
AbbVie (ABBV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Income Stocks to Buy for May 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 22nd.
This Book Changed Warren Buffett's Life
by Tracey Ryniec
With the coronavirus crisis throwing investors for a loop, it's time to consult with the father of value investing, Benjamin Graham.
Simple Secrets Anyone Can Use to Reach Early Retirement - May 21, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
3 Top Dividend Stocks to Maximize Your Retirement Income - May 20, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat
by Zacks Equity Research
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
AbbVie, Interactive, Inphi, Chegg and ServiceNow highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
AbbVie, Interactive, Inphi, Chegg and ServiceNow highlighted as Zacks Bull and Bear of the Day
3 Value Stocks That Could Thrive in a Post-Pandemic World
by Zacks Equity Research
With an economic revival in motion despite the unfavorable circumstances so far, value stocks offer the much-needed stability to one's portfolio.
J&J to Stop Sale of Talc-Based Baby Powder in North America
by Zacks Equity Research
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.
Bull of the Day: AbbVie (ABBV)
by David Borun
With profitable products on the market and a powerful pipeline, AbbVie is a defensive stock with growth potential
Bear of the Day: InterActive Corp (IAC)
by David Borun
This already high-priced stock has become even more expensive after a huge recovery rally.
Top Ranked Value Stocks to Buy for May 20th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, May 20th
AbbVie (ABBV) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABBV) Outperforming Other Medical Stocks This Year?
New Strong Buy Stocks For May 19th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Is AbbVie (ABBV) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Extreme Risks of Trading Your Own Retirement Assets - May 18, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
The Zacks Analyst Blog Highlights: JPMorgan Chase, AbbVie, Royal Dutch Shell, Gilead Sciences and Anthem
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan Chase, AbbVie, Royal Dutch Shell, Gilead Sciences and Anthem
Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY
by Kinjel Shah
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.
Top Stock Reports for JPMorgan, AbbVie & Royal Dutch Shell
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), AbbVie (ABBV) and Royal Dutch Shell (RDS.A).
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - May 14, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Powerful Proof Anyone Can Invest for an Early Retirement - May 13, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Simple Market Timing Strategies That Work - May 12, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Reata (RETA) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Reata (RETA) reports narrower-than-expected loss but misses revenue estimates for first-quarter 2020. Shares down.